Recently, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (hereinafter referred to as “Yiling Pharmaceutical”) applied for a patent “Preparation process and application of spunbonded non-woven fabric containing Lianhua Qingwen extract” , which has attracted widespread attention.
According to Zhihuiya New Drug Information Database , Yiling Pharmaceutical was established in 1992 and currently focuses on the nervous system, endocrine and metabolic diseases, tumors, infections, immune system, blood and lymphatic system and other diseases. Among the drugs under research, there are mainly two kinds of traditional Chinese medicines and small molecule chemical drugs . The most commonly developed targets are FLT3 and COXs. As of December 7, Yiling Pharmaceutical and its affiliated subsidiaries have 15 drug development pipelines. , of which 8 drugs have been approved for marketing.
Figure 1: Yiling Pharmaceutical’s disease domain intelligence(Source: Zhihuiya New Drug Information Database)
Judging from the above 15 drug development pipelines, their indications are mainly distributed in the fields of depression, diabetes, and new coronavirus pneumonia, and they are in different stages of new drug development.
In addition, according to Wisdom Bud data, Yiling Pharmaceutical currently has more than 670 published patent applications. Based on the comprehensive analysis and evaluation of the company’s competitiveness, R&D scale and stability, technical layout, technical quality, and technical influence, Shijiazhuang Yiling Pharmaceutical Co., Ltd.’sscientific and technological innovation ability in the biomedical industry is rated as AA grade; at the same time, the company ranks 26th among more than 24,000 biopharmaceutical companies that have been included in the platform, and ranks 2nd among more than 630 biopharmaceutical companies that have been included in Hebei Province .
Figure 2: Yiling Pharmaceutical Science and Technology Innovation Evaluation(Source: Wisdom Buds Creativity Evaluation Platform)
Further analysis of the above-mentioned authorized patent “Preparation process and application of spunbond non-woven fabric containing Lianhua Qingwen extract” shows that the beneficial effect of this invention is: through the proportioning and processing of polymer raw materials, the final spunbond The non-woven fabric contains Lianhua Qingwen extract, and the prepared spunbonded non-woven fabric can have anti-inflammatory, antibacterial, and antiviral functions when applied to skin-contact clothing, home textiles, or medical protective products , has a good inhibitory effect on the novel coronavirus. At the same time, when applied to masks, it not only has anti-inflammatory, anti-bacterial, and anti-viral properties, but also Chinese medicine ingredients can absorb moisture around the mouth and nose, avoiding bacterial growth and other complications. In addition, 68% of the active ingredients of Lianhua Qingwen can be attached to the spunbonded nonwoven fabric through the preparation process.
Figure 3: Interpretation of the patent “Preparation process and application of spunbonded non-woven fabric containing Lianhua Qingwen extract” (source: Wisdom Bud R&D Information Database)